Previous 10 | Next 10 |
Amid widespread uncertainty in healthcare around COVID-19 impact, Baird is focusing on clinical catalysts that continue to power biotech picks - and in particular it's declaring fresh picks on two stocks with data forthcoming. More news on: Constellation Pharmaceuticals, Inc., Blueprint Me...
CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announc...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
April 9, 2020 Palm Beach, FL – April 9, 2020 – Recent industry reports on the projected growth of the global dermatologicals markets predict a continued surge in revenues. A report from Allied Market Research said that the global dermatologicals market is expected to...
Shares of Mersana Therapeutics (NASDAQ: MRSN) , a clinical-stage biotechnology company, are surging today after it raised more capital than expected in a secondary share offering. Seeing the company raise $65 million to develop novel cancer therapies pushed the stock 20.2% higher as of 2...
Mersana Therapeutics (NASDAQ: MRSN ) has raised gross proceeds of ~$65M through At-the-Market facility with from several investors. More news on: Mersana Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announc...
Shares of Mersana Therapeutics (NASDAQ: MRSN) , a clinical-stage biopharmaceutical company, are falling after the company released clinical-trial results for its lead candidate. Investors weren't thrilled with the data and pushed the stock 14.9% lower as of 3:13 p.m. EST on Tuesday....
Mersana Therapeutics (NASDAQ: MRSN ) has posted updated data from its XMT-1536 Phase 1 dose escalation study. More news on: Mersana Therapeutics, Inc., Healthcare stocks news, Read more ...
- Well tolerated at doses up to 43 mg/m 2 with encouraging activity in heavily pre-treated patient populations - Favorable trend towards higher response rates with higher NaPi2b expression - On track for interim disclosure of Phase 1 expansion cohort data in Q2 2020 CAMBRIDGE, ...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...